Pila Pharma AB (publ) (PILA.ST)
SEK 3.05
(1.84%)
SEK 3.05
(1.84%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -8.81 Million SEK | 40.1% |
| 2022 | -26.76 Million SEK | 3.96% |
| 2021 | -17.15 Million SEK | -175.08% |
| 2020 | -3.35 Million SEK | 28.5% |
| 2019 | -8.64 Million SEK | 4.76% |
| 2018 | -4.93 Million SEK | -3.09% |
| 2017 | -4.73 Million SEK | -27769.48% |
| 2016 | -17.17 Thousand SEK | -4027.4% |
| 2015 | -416.00 SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.77 Million SEK | 0.0% |
| 2024 Q1 | -1.77 Million SEK | -76.49% |
| 2023 Q2 | -1.48 Million SEK | 5.52% |
| 2023 Q4 | -1 Million SEK | 19.55% |
| 2023 Q1 | -1.57 Million SEK | 94.37% |
| 2023 Q3 | -1.24 Million SEK | 16.06% |
| 2023 FY | - SEK | 40.1% |
| 2022 Q4 | -27.96 Million SEK | -4395.25% |
| 2022 Q2 | -2.24 Million SEK | 6.38% |
| 2022 FY | - SEK | 3.96% |
| 2022 Q1 | -2.39 Million SEK | 22.03% |
| 2022 Q3 | 651 Thousand SEK | 129.0% |
| 2021 Q1 | -2.45 Million SEK | -52.11% |
| 2021 FY | - SEK | -175.08% |
| 2021 Q4 | -3.07 Million SEK | 2.95% |
| 2021 Q3 | -3.16 Million SEK | -99.31% |
| 2021 Q2 | -1.59 Million SEK | 35.29% |
| 2020 Q3 | -289 Thousand SEK | 0.0% |
| 2020 FY | - SEK | 28.5% |
| 2020 Q4 | -1.61 Million SEK | -458.91% |
| 2019 FY | - SEK | 4.76% |
| 2018 FY | - SEK | -3.09% |
| 2017 FY | - SEK | -27769.48% |
| 2016 FY | - SEK | -4027.4% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | 79.92% |
| Amniotics AB (publ) | -27.14 Million SEK | 67.533% |
| BioArctic AB (publ) | 275.38 Million SEK | 103.2% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 97.604% |
| Camurus AB (publ) | 562.54 Million SEK | 101.567% |
| Cantargia AB (publ) | -284.31 Million SEK | 96.9% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 54.99% |
| CombiGene AB (publ) | -35.33 Million SEK | 75.061% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 93.743% |
| Genovis AB (publ.) | 64.57 Million SEK | 113.648% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 92.331% |
| Mendus AB (publ) | -97.84 Million SEK | 90.994% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 76.198% |
| Intervacc AB (publ) | -68.98 Million SEK | 87.225% |
| Kancera AB (publ) | -61.88 Million SEK | 85.761% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 67.097% |
| LIDDS AB (publ) | -39.67 Million SEK | 77.786% |
| Lipum AB (publ) | -37.11 Million SEK | 76.259% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 27.194% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 128.062% |
| NextCell Pharma AB | -40.98 Million SEK | 78.498% |
| OncoZenge AB (publ) | 7.26 Million SEK | 221.284% |
| Saniona AB (publ) | -69.69 Million SEK | 87.356% |
| Simris Alg AB (publ) | -22.36 Million SEK | 60.593% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 97.224% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 96.875% |
| Xintela AB (publ) | -53.47 Million SEK | 83.519% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 94.811% |
| Ziccum AB (publ) | -20.34 Million SEK | 56.678% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 38.015% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 48.418% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 440723.9% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 96.291% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -323.677% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 34.387% |
| Corline Biomedical AB | -1.69 Million SEK | -421.14% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 94.916% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 83.921% |
| Aptahem AB (publ) | -10 Million SEK | 11.956% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 176.305% |
| Fluicell AB (publ) | -25.91 Million SEK | 65.993% |
| Biovica International AB (publ) | -119.5 Million SEK | 92.626% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 79.129% |
| AcouSort AB (publ) | -16.7 Million SEK | 47.24% |
| Abliva AB (publ) | -93.6 Million SEK | 90.586% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 97.238% |
| 2cureX AB (publ) | -35.13 Million SEK | 74.919% |
| I-Tech AB | 30.34 Million SEK | 129.041% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 98.767% |
| Cyxone AB (publ) | -20.41 Million SEK | 56.831% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 91.399% |
| Biosergen AB | 228 Thousand SEK | 3965.122% |
| Nanologica AB (publ) | -62.11 Million SEK | 85.814% |
| SynAct Pharma AB | -222.7 Million SEK | 96.043% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 79.908% |
| BioInvent International AB (publ) | -312.7 Million SEK | 97.182% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 2948.128% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 21082.59% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 96.195% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 91.882% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 23.163% |